Novartis Farma

Novartis Farma is a pharmaceutical operating entity associated with the Novartis Group, the Swiss multinational healthcare company headquartered in Basel. Novartis describes itself as pursuing scientific breakthroughs for one purpose: people, and states that it has operated for more than 250 years of scientific heritage and 30 years under the Novartis name. The group discovers, develops, manufactures and markets prescription medicines across therapeutic areas including oncology, neuroscience, ophthalmology and immunology, and distributes them through US and international units. The Novartis product portfolio is broad and global. According to the company's own product listing, treatments include Adakveo (crizanlizumab) in oncology, Aimovig (erenumab) in neuroscience, Beovu (brolucizumab) and Azarga/Azorga (brinzolamide, timolol) in ophthalmology, and Afinitor/Votubia (everolimus) in oncology, among many others. The company notes that not all treatments are available in all countries, and its medicines reach markets such as the United States, Germany, Australia, the United Kingdom, Austria, Poland, the Netherlands, Canada, Turkey, Russia, Japan and Finland. As part of the Novartis Group, Novartis Farma operates within a corporate governance framework set out in the Articles of Incorporation, Board Regulations and committee charters. Novartis is committed to good corporate governance and publishes an Annual Report, a Report on Nonfinancial Matters and other reporting documents. The group also frames environmental, social and governance (ESG) priorities as core to its strategy, including inclusive access to innovation and environmental sustainability. Novartis Farma SA is also recorded as a company in Porto Salvo, Portugal, reflecting the group's local operating presence in that market. The entity therefore represents the commercial and regulatory face of Novartis medicines in the territories it serves, rather than a separately branded consumer product line.

Novartis traces its scientific heritage back more than 250 years, and the Novartis name itself was created 30 years ago through the merger of Ciba-Geigy and Sandoz. The company describes this legacy as the foundation for its current mission: to pursue scientific breakthroughs for one purpose — people. Over three decades as Novartis, the group has built a portfolio of prescription medicines across oncology, neuroscience, ophthalmology and other therapeutic areas, and has expanded into markets worldwide. Novartis Farma operates as part of this group structure. The entity is associated with the Novartis Group's commercial and regulatory activities, including a registered presence in Porto Salvo, Portugal, as recorded in public company data. Within the group, products are offered through US and international units, and the company notes that not all treatments are available in all countries. Its medicines have reached patients in markets including the United States, Germany, Australia, the United Kingdom, Austria, Poland, the Netherlands, Canada, Turkey, Russia, Japan and Finland. In recent years, Novartis has continued to advance its pipeline and portfolio. In September 2026, the company received a positive CHMP opinion for Cosentyx in polymyalgia rheumatica and provided an update on the Phase III HARBOR study of delpacibart etedesiran for myotonic dystrophy type 1. The group also participates in industry-level advocacy, joining other pharmaceutical chairs in an open letter warning that Europe is losing the pharma investment race while arguing that a comeback is within reach. Corporate governance and sustainability are central to the group's operating model. Novartis states that its principles and rules on corporate governance are laid down in the Articles of Incorporation, the Regulations of the Board and the Charters of the Board Committees, and it publishes an Annual Report, a Report on Nonfinancial Matters and quarterly impact and sustainability updates. The company frames ESG as a core business objective, emphasizing inclusive access to innovation and environmental sustainability.

• 2026

  Novartis marks 30 years as a company, describing a legacy of more than 250 years of scientific innovation.

• 1996

  Novartis is created through the merger of Ciba-Geigy and Sandoz, establishing the Novartis name.

• Novartis receives a positive CHMP opinion for Cosentyx in polymyalgia rheumatica.

• Novartis provides an update on the Phase III HARBOR study of delpacibart etedesiran for myotonic dystrophy type 1.

A science-driven medicines company within the Novartis Group, focused on turning innovation into treatments that redefine care for patients.

• Adakveo (crizanlizumab)

• Afinitor/Votubia (everolimus)

• Aimovig (erenumab)

• Arzerra (ofatumumab)

• Azarga/Azorga (brinzolamide, timolol)

• Beovu (brolucizumab)

• Betoptic S

• Ciprodex (ciprofloxacin, dexamethasone)

• Cosentyx (secukinumab)

• 2021-02-28

  Novartis China and Beijing Pain Challenge Foundation release multiple sclerosis documentary[6]诺华中国与北京病痛挑战公益基金会联合发布多发性硬化患者纪录片prnasia.com

  Reported: 2021-02-28

  Novartis China and the Beijing Pain Challenge Foundation jointly released the documentary 《让爱可及》 about a person’s experience with multiple sclerosis.

1. 1Novartisnovartis.com
2. 2Products | Novartisnovartis.com
3. 3Corporate governance | Novartisnovartis.com
4. 4ESG | Novartisnovartis.com
5. 5Novartis Farma SA (Portugal) - Wikidatawikidata.org
6. 6诺华中国与北京病痛挑战公益基金会联合发布多发性硬化患者纪录片prnasia.com